This episode explores a study led by Dr. Shuai Huang from Beijing Hospital, examining the efficacy and safety of combining anlotinib, a multi-target tyrosine kinase inhibitor, with oral etoposide for treating platinum-resistant ovarian cancer. In a retrospective analysis of 22 patients, the combination therapy achieved a partial response rate of 45% and a disease control rate of 85%, with a median progression-free survival of 8.7 months. While all patients experienced adverse events, severe toxicities were manageable in most cases, though two patients discontinued treatment. The study highlights the potential of this oral regimen as a promising outpatient option, though further randomized trials are needed to validate its findings. Tune in to learn more about this innovative approach.

Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer (https://doi.org/10.3802/jgo.2024.35.e100)